Smarter Decisions,
Better Care

UpToDate synthesizes the most recent medical information into evidence-based practical recommendations clinicians trust to make the right point-of-care decisions.

  • Rigorous editorial process: Evidence-based treatment recommendations
  • World-Renowned physician authors: over 5,100 physician authors and editors around the globe
  • Innovative technology: integrates into the workflow; access from EMRs

Choose from the list below to learn more about subscriptions for a:


Subscribers log in here


Pathogenesis of ovarian hyperstimulation syndrome

INTRODUCTION

Ovarian hyperstimulation syndrome (OHSS) refers to a combination of ovarian enlargement due to multiple ovarian cysts and an acute fluid shift out of the intravascular space. The ovarian cysts are the result of multifollicular development. The most severe manifestations of the syndrome include massive ovarian enlargement from multiple cysts and, due to fluid movement out of the intravascular space, hemoconcentration and third-space accumulation of fluid; these changes may be complicated by renal failure, hypovolemic shock, thromboembolic episodes, acute respiratory distress syndrome, and death [1,2].

The pathogenesis of OHSS will be reviewed here. The classification, prevention, and treatment of this disorder are discussed separately. (See "Classification and treatment of ovarian hyperstimulation syndrome" and "Prevention of ovarian hyperstimulation syndrome".)

SPONTANEOUS VERSUS INDUCED OVULATION

In spontaneous ovulatory cycles, hypothalamic-pituitary-ovarian feedback mechanisms limit follicle recruitment to a small number of early antral follicles. Full development is generally restricted to a single leading follicle that will ovulate in response to the midcycle luteinizing hormone (LH) surge. (See "Physiology of the normal menstrual cycle".)

By comparison, ovulation induction involves administration of a pharmacological dose of exogenous gonadotropins, thereby overriding normal feedback mechanisms. This results in recruitment of a large number of antral follicles, several of which are sustained as leading follicles capable of either luteinization or ovulation. The monofollicular development that occurs in spontaneous cycles is extremely difficult to duplicate in stimulated cycles, even with meticulous ultrasound and serum estradiol monitoring. (See "Overview of ovulation induction".)

ETIOLOGY

Exogenous gonadotropins — Ovarian hyperstimulation occurs after luteinization of a large number of follicles. Such massive follicular luteinization is usually only observed in exogenous gonadotropin cycles following administration of human chorionic gonadotropin (hCG), or after administration of gonadotropin releasing hormone (GnRH) agonist; it rarely occurs in women treated with clomiphene citrate. (See "Ovulation induction with clomiphene citrate".) The clinical symptoms usually appear 5 to 10 days following the first dose of the ovulatory trigger (hCG, GnRH agonist). (See "Overview of ovulation induction".)

      

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Nov 2014. | This topic last updated: Jan 6, 2008.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2014 UpToDate, Inc.
References
Top
  1. Elchalal U, Schenker JG. The pathophysiology of ovarian hyperstimulation syndrome--views and ideas. Hum Reprod 1997; 12:1129.
  2. Kaiser UB. The pathogenesis of the ovarian hyperstimulation syndrome. N Engl J Med 2003; 349:729.
  3. Chae HD, Park EJ, Kim SH, et al. Ovarian hyperstimulation syndrome complicating a spontaneous singleton pregnancy: a case report. J Assist Reprod Genet 2001; 18:120.
  4. Nappi RG, Di Naro E, D'Aries AP, Nappi L. Natural pregnancy in hypothyroid woman complicated by spontaneous ovarian hyperstimulation syndrome. Am J Obstet Gynecol 1998; 178:610.
  5. Zalel Y, Orvieto R, Ben-Rafael Z, et al. Recurrent spontaneous ovarian hyperstimulation syndrome associated with polycystic ovary syndrome. Gynecol Endocrinol 1995; 9:313.
  6. Smits G, Olatunbosun O, Delbaere A, et al. Ovarian hyperstimulation syndrome due to a mutation in the follicle-stimulating hormone receptor. N Engl J Med 2003; 349:760.
  7. Vasseur C, Rodien P, Beau I, et al. A chorionic gonadotropin-sensitive mutation in the follicle-stimulating hormone receptor as a cause of familial gestational spontaneous ovarian hyperstimulation syndrome. N Engl J Med 2003; 349:753.
  8. Montanelli L, Delbaere A, Di Carlo C, et al. A mutation in the follicle-stimulating hormone receptor as a cause of familial spontaneous ovarian hyperstimulation syndrome. J Clin Endocrinol Metab 2004; 89:1255.
  9. Engel T, Jewelewicz R, Dyrenfurth I, et al. Ovarian hyperstimulation syndrome. Report of a case with notes on pathogenesis and treatment. Am J Obstet Gynecol 1972; 112:1052.
  10. Yan Z, Weich HA, Bernart W, et al. Vascular endothelial growth factor (VEGF) messenger ribonucleic acid (mRNA) expression in luteinized human granulosa cells in vitro. J Clin Endocrinol Metab 1993; 77:1723.
  11. McClure N, Healy DL, Rogers PA, et al. Vascular endothelial growth factor as capillary permeability agent in ovarian hyperstimulation syndrome. Lancet 1994; 344:235.
  12. Shweiki D, Itin A, Neufeld G, et al. Patterns of expression of vascular endothelial growth factor (VEGF) and VEGF receptors in mice suggest a role in hormonally regulated angiogenesis. J Clin Invest 1993; 91:2235.
  13. Levin ER, Rosen GF, Cassidenti DL, et al. Role of vascular endothelial cell growth factor in Ovarian Hyperstimulation Syndrome. J Clin Invest 1998; 102:1978.
  14. Agrawal R, Tan SL, Wild S, et al. Serum vascular endothelial growth factor concentrations in in vitro fertilization cycles predict the risk of ovarian hyperstimulation syndrome. Fertil Steril 1999; 71:287.
  15. Insler, V, Lunenfeld, B. Pathogenesis of ovarian hyperstimulation syndrome. In: In Vitro Fertilization and Assisted Reproduction, Edts. V. Gomel & P.C.K. Leung, Monduzzi Editore, Bologna, 1997, pp. 433-439.
  16. Whelan JG 3rd, Vlahos NF. The ovarian hyperstimulation syndrome. Fertil Steril 2000; 73:883.
  17. Navot, D, Bergh, PA, Palermo, R. Pathophysiology and clinical management of ovarian hyperstimulation. In: Ovulation Induction, Edts. M. Filicori & C. Flamigni, Elsevier Science BV, Amsterdam, 1994, pp. 319.
  18. Ujioka T, Matsuura K, Tanaka N, Okamura H. Involvement of ovarian kinin-kallikrein system in the pathophysiology of ovarian hyperstimulation syndrome: studies in a rat model. Hum Reprod 1998; 13:3009.
  19. Daniel Y, Geva E, Amit A, et al. Soluble endothelial and platelet selectins in serum and ascitic fluid of women with ovarian hyperstimulation syndrome. Am J Reprod Immunol 2001; 45:154.
  20. Polishuk WZ, Schenker JG. Ovarian overstimulation syndrome. Fertil Steril 1969; 20:443.